Total number of cells in bone marrow was calculated by multiplying the number of cells from two femurs ×7.9 [69], [69].
The absorbed dose to the bone marrow was calculated.
For all patients the absorbed radiation dose to the bone marrow was calculated according to the MIRD scheme (Eq. 1).
The radiation dose to the bone marrow is usually calculated according to the MIRD scheme, where the accumulated activity in the bone marrow is calculated from the accumulated radioactivity of the radiopharmaceutical in the blood.
Therefore it was not possible to place a ROI reliably, and consequently no absorbed dose to the bone marrow was calculated from SPECT scans.
Assuming no specific uptake in the red marrow, a uniform distribution of the radioactivity, and that the red marrow clearance was the same as in blood, the self-dose to the red marrow was calculated.
The residence time for the red marrow is calculated from the residence time for blood, with the assumption that nonspecific uptake of the radiolabel takes place in the bone marrow.
The activity of F-FDG to deliver 300 rad to the red marrow was calculated to be 7.14 Ci, and tumor doses would be 330, 1650, and 3300 rad for SUVs of 1, 5, and 10, respectively.
The absorbed radiation doses to dose-limiting organs such as the kidneys and bone marrow are calculated to better tailor the total cumulative activity that can be administered to the individual patient.
The activity of F-FDG to deliver 200 rad to the red marrow was calculated to be 4.76 Ci for a 70 kg woman, and the subsequent tumor doses were calculated to be 220, 1100, and 2200 rad for SUVs of 1, 5, and 10, respectively.
